[1]
|
Valastyan, S. and Weinberg, R.A. (2011) Tumor Metastasis: Molecular Insights and Evolving Paradigms. Cell, 147, 275-292. https://doi.org/10.1016/j.cell.2011.09.024
|
[2]
|
Damineni, S., Rao, V.R., Kumar, S., et al. (2014) Germline Mutations of TP53 Gene in Breast Cancer. Tumor Biology, 35, 9219-9227. https://doi.org/10.1007/s13277-014-2176-6
|
[3]
|
Siegel, R.L., Miller, K.D., Wagle, N.S., et al. (2023) Cancer Sta-tistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763
|
[4]
|
刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-13.
|
[5]
|
Lawrence, M.S., Stojanov, P., Mermel, C.H., et al. (2014) Discovery and Saturation Analysis of Cancer Genes across 21 Tumour Types. Nature, 505, 495-501. https://doi.org/10.1038/nature12912
|
[6]
|
Sirico, M., D’Angelo, A., Gianni, C., et al. (2023) Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. Cancers, 15, 703. https://doi.org/10.3390/cancers15030703
|
[7]
|
Hennessy, B.T., Smith, D.L., Ram, P.T., et al. (2005) Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. Nature Reviews Drug Discovery, 4, 988-1004. https://doi.org/10.1038/nrd1902
|
[8]
|
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., et al. (2010) The Emerging Mechanisms of Isoform-Specific PI3K Signalling. Nature Reviews Molecular Cell Biology, 11, 329-341. https://doi.org/10.1038/nrm2882
|
[9]
|
Thorpe, L.M., Yuzugullu, H. and Zhao, J.J. (2015) PI3K in Cancer: Diver-gent Roles of Isoforms, Modes of Activation and Therapeutic Targeting. Nature Reviews Cancer, 15, 7-24. https://doi.org/10.1038/nrc3860
|
[10]
|
Engelman, J.A. (2009) Targeting PI3K Signalling in Cancer: Opportunities, Challenges and Limitations. Nature Reviews Cancer, 9, 550-562. https://doi.org/10.1038/nrc2664
|
[11]
|
Hanker, A.B., Kaklamani, V. and Arteaga, C.L. (2019) Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors What Limits the Success of PI3K Inhibitors? Cancer Discovery, 9, 482-491. https://doi.org/10.1158/2159-8290.CD-18-1175
|
[12]
|
Okkenhaug, K., Graupera, M. and Vanhaesebroeck, B. (2016) Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy PI3K Isoform Function in the Tumor Stroma. Cancer Discovery, 6, 1090-1105. https://doi.org/10.1158/2159-8290.CD-16-0716
|
[13]
|
O’Donnell, J.S., Massi, D., Teng, M.W., et al. (2018) PI3K-AKT-mTOR Inhibition in Cancer Immunotherapy, Redux. Seminars in Cancer Biology, 48, 91-103. https://doi.org/10.1016/j.semcancer.2017.04.015
|
[14]
|
Jean, S. and Kiger, A.A. (2014) Classes of Phosphoinositide 3-Kinases at a Glance. Journal of Cell Science, 127, 923-928. https://doi.org/10.1242/jcs.093773
|
[15]
|
Toker, A. and Cantley, L.C. (1997) Signalling through the Lipid Products of Phosphoinositide-3-OH Kinase. Nature, 387, 673-676. https://doi.org/10.1038/42648
|
[16]
|
Folkes, A.J., Ahmadi, K., Alderton, W.K., et al. (2008) The Identification of 2-(1H-indazol-4-yl)-6-(4-methanesul- fonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer. Journal of Medicinal Chemistry, 51, 5522-5532. https://doi.org/10.1021/jm800295d
|
[17]
|
Burke, J.E. (2018) Structural Basis for Regulation of Phosphoinositide Kinases and Their Involvement in Human Disease. Molecular Cell, 71, 653-673. https://doi.org/10.1016/j.molcel.2018.08.005
|
[18]
|
Kriplani, N., Hermida, M.A., Brown, E.R., et al. (2015) Class IPI3-Kinases: Function and Evolution. Advances in Biological Regulation, 59, 53-64. https://doi.org/10.1016/j.jbior.2015.05.002
|
[19]
|
Bilanges, B., Posor, Y. and Vanhaesebroeck, B. (2019) PI3K Isoforms in Cell Signalling and Vesicle Trafficking. Nature Reviews Molecular Cell Biology, 20, 515-534. https://doi.org/10.1038/s41580-019-0129-z
|
[20]
|
Arcucci, S., Ramos-Delgado, F., Cayron, C., et al. (2021) Organ-ismal Roles for the PI3Kα and β Isoforms: Their Specificity, Redundancy or Cooperation Is Context-Dependent. Bio-chemical Journal, 478, 1199-1225.
https://doi.org/10.1042/BCJ20210004
|
[21]
|
Gerstung, M., Jolly, C., Leshchiner, I., et al. (2020) The Evolutionary History of 2,658 Cancers. Nature, 578, 122-128.
https://doi.org/10.1038/s41586-019-1907-7
|
[22]
|
He, Y., Sun, M.M., Zhang, G.G., et al. (2021) Targeting PI3K/Akt Signal Transduction for Cancer Therapy. Signal Transduction and Targeted Therapy, 6, 425. https://doi.org/10.1038/s41392-021-00828-5
|
[23]
|
Herman, S.E., Gordon, A.L., Wagner, A.J., et al. (2010) Phos-phatidylinositol 3-Kinase-δ Inhibitor CAL-101 Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia by Antagonizing Intrinsic and Extrinsic Cellular Survival Signals. Blood: The Journal of the American Society of Hema-tology, 116, 2078-2088.
https://doi.org/10.1182/blood-2010-02-271171
|
[24]
|
Tsolakos, N., Durrant, T., Chessa, T., et al. (2018) Quantita-tion of Class IA PI3Ks in Mice Reveals p110-Free-p85s and Isoform-Selective Subunit Associations and Recruitment to Receptors. Proceedings of the National Academy of Sciences, 115, 12176-12181. https://doi.org/10.1073/pnas.1803446115
|
[25]
|
Mishra, R., Patel, H., Alanazi, S., et al. (2021) PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects. International Journal of Molecular Sciences, 22, Article No. 3464. https://doi.org/10.3390/ijms22073464
|
[26]
|
Braccini, L., Ciraolo, E., Campa, C.C., et al. (2015) PI3K-C2γ Is a Rab5 Effector Selectively Controlling Endosomal Akt2 Activation Downstream of Insulin Signalling. Nature Communications, 6, Article No. 7400.
https://doi.org/10.1038/ncomms8400
|
[27]
|
Gulluni, F., Martini, M., De Santis, M.C., et al. (2017) Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function. Cancer Cell, 32, 444-459.e447.
https://doi.org/10.1016/j.ccell.2017.09.002
|
[28]
|
Gulluni, F., De Santis, M.C., Margaria, J.P., et al. (2019) Class II PI3K Functions in Cell Biology and Disease. Trends in Cell Biology, 29, 339-359. https://doi.org/10.1016/j.tcb.2019.01.001
|
[29]
|
Marat, A.L. and Haucke, V. (2016) Phosphatidylinositol 3‐Phosphates—At the Interface between Cell Signalling and Membrane Traffic. The EMBO Journal, 35, 561-579. https://doi.org/10.15252/embj.201593564
|
[30]
|
O’Farrell, F., Lobert, V.H., Sneeggen, M., et al. (2017) Class III Phosphatidylinositol-3-OH Kinase Controls Epithelial Integrity through Endosomal LKB1 Regulation. Nature Cell Biol-ogy, 19, 1412-1423. https://doi.org/10.1038/ncb3631
|
[31]
|
Stjepanovic, G., Baskaran, S., Lin, M.G., et al. (2017) Vps34 Kinase Domain Dynamics Regulate the Autophagic PI 3-Kinase Complex. Molecular Cell, 67, 528-534.e523. https://doi.org/10.1016/j.molcel.2017.07.003
|
[32]
|
Xu, Z., Han, X., Ou, D., et al. (2020) Targeting PI3K/AKT/mTOR-Mediated Autophagy for Tumor Therapy. Applied Microbiology and Biotechnology, 104, 575-587. https://doi.org/10.1007/s00253-019-10257-8
|
[33]
|
Ramaswamy, B., Lu, Y., Teng, K.-Y., et al. (2012) Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway. Cancer Research, 72, 5048-5059.
https://doi.org/10.1158/0008-5472.CAN-12-1248
|
[34]
|
Hong, S., Zhang, H., Can, X., et al. (2009) Clinicopatho-logical Research and Expression of PTEN/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer. Chinese Jour-nal of Lung Cancer, 12, 889-892.
|
[35]
|
Brennan, C.W., Verhaak, R.G., McKenna, A., et al. (2013) The Somatic Ge-nomic Landscape of Glioblastoma. Cell, 155, 462-477. https://doi.org/10.1016/j.cell.2013.09.034
|
[36]
|
Mackay, A., Burford, A., Carvalho, D., et al. (2017) Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 32, 520-537.e5. https://doi.org/10.1016/j.ccell.2017.08.017
|
[37]
|
The Cancer Genome Atlas Network (2012) Comprehensive Molecular Portraits of Human Breast Tumours. Nature, 490, 61-70. https://doi.org/10.1038/nature11412
|
[38]
|
Akbani, R., Akdemir, K.C., Aksoy, B.A., et al. (2015) Genomic Classi-fication of Cutaneous Melanoma. Cell, 161, 1681-1696. https://doi.org/10.1016/j.cell.2015.05.044
|
[39]
|
Thakur, A., Tawa, G.J., Henderson, M.J., et al. (2020) Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-based hy-droxamic Acids as Dual PI3K/HDAC Inhibitors. Journal of Medicinal Chemistry, 63, 4256-4292.
https://doi.org/10.1021/acs.jmedchem.0c00193
|
[40]
|
Lee, Y.-R., Chen, M. and Pandolfi, P.P. (2018) The Functions and Regulation of the PTEN Tumour Suppressor: New Modes and Prospects. Nature Reviews Molecular Cell Biology, 19, 547-562.
https://doi.org/10.1038/s41580-018-0015-0
|
[41]
|
Robbins, H.L. and Hague, A. (2016) The PI3K/Akt Pathway in Tumors of Endocrine Tissues. Frontiers in Endocrinology, 6, Article No. 188. https://doi.org/10.3389/fendo.2015.00188
|
[42]
|
Courtney, K.D., Corcoran, R.B. and Engelman, J.A. (2010) The PI3K Pathway as Drug Target in Human Cancer. Journal of Clinical Oncology, 28, 1075-1083. https://doi.org/10.1200/JCO.2009.25.3641
|
[43]
|
Brana, I. and Siu, L.L. (2012) Clinical Development of Phosphati-dylinositol 3-Kinase Inhibitors for Cancer Treatment. BMC Medicine, 10, Article No. 161. https://doi.org/10.1186/1741-7015-10-161
|
[44]
|
Sarbassov, D.D., Guertin, D.A., Ali, S.M., et al. (2005) Phos-phorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex. Science, 307, 1098-1101. https://doi.org/10.1126/science.1106148
|